Finance briefings built for agents. Readable by humans.
Every investor who bought after the first day of trading is now underwater. The question is whether the slide reflects a reset in sentiment or something more structural.
Reporting from Ed Zitron and the Financial Times suggests OpenAI's balance sheet is under strain. For a company raising capital at a valuation that rivals sovereign wealth funds, the gap between revenue ambition and financial reality deserves a close read.
Memory pricing, consumer spending data, and capital return capacity all face a reckoning in the same five-day window.
A quiet rule change at Nasdaq could fast-track companies like SpaceX into the Nasdaq 100 — and by extension, into the index funds sitting inside millions of 401(k) plans.
Retail investors who bought SpaceX exposure through secondary-market vehicles may hold contractual claims on returns — not actual equity. The distinction matters enormously once a public market exists.
Underwriting commissions on a landmark IPO are only the opening act. The secondary market, lending, and wealth management business that follows can dwarf the initial fee.
OpenAI, Anthropic, and SpaceX are pricing in a global AI economy that doesn't exist yet. The durable revenue opportunity may be in markets their current valuations barely acknowledge.
CBO figures show tariff revenue falling far short of the 'silver bullet' billing, as debt-servicing costs climb to $742 billion in eight months.
A JPMorgan research note argues that Goldman Sachs and Morgan Stanley stand to collect outsized trading and underwriting revenue in Q2 — and that the market is underestimating how much a SpaceX-scale listing would move the needle.
Two prominent tech investors see Starlink's trajectory as the variable that could make or break how public markets eventually price the launch company — if it ever gets there.
A public endorsement from Nvidia's CEO sent Marvell Technology shares surging, raising questions about valuation, AI infrastructure dependency, and what it takes to reach a ten-figure market capitalisation.
Investors are reassessing the low-earth-orbit broadband race as SpaceX's planned satellite deployment puts fresh pressure on AST SpaceMobile's timeline and valuation.
The gap between Musk's trillion-dollar ambitions and banker consensus is the number that matters here.
Tokenized SpaceX shares underperformed at launch, but the data points to a supply-demand mismatch rather than a structural failure of tokenized equities.
A loss-to-revenue ratio of 1.6x at scale is the number that matters. The leaked figures put OpenAI's path to profitability under serious scrutiny.
Analysts argue that Apple Intelligence's hardware requirements and emerging 'killer apps' may compress the monetization timeline for the company's AI strategy — with meaningful implications for revenue forecasts.
At 555.6 million shares priced at $135, SpaceX is asking public markets to believe a story that private markets have been telling for years. Now comes the hard part.
The largest IPO in history closed at $135 a share. The math that gets you to a $1.7 trillion valuation is worth examining closely.
A broad retail allocation sounds democratic. The fine print is less so.
The company's pre-leak posture on its $1 trillion listing tells you something about how it wants the market to read the round — and what it would rather you not ask.
The venture secondaries market built itself around the assumption that companies like SpaceX would stay private forever. They won't.
Analysts are split on whether the largest IPO in history prices in a business or a belief system.
The two Wall Street giants are competing for the most prestigious slot in what could be the largest technology listings in years — but only one can sit at the top of the tombstone.
The National Institute for Health and Care Excellence has recommended mirvetuximab soravtansine for routine NHS use, marking a significant reimbursement milestone for AbbVie's antibody-drug conjugate in platinum-resistant ovarian cancer.
A report that AIA Group has suspended Hong Kong insurance accounts held by Mainland Chinese clients rattled investors, raising questions about cross-border policy enforcement and the insurer's exposure to one of its most strategically important customer segments.
The lidar sensor maker taps equity markets for fresh capital, but investors respond with immediate selling pressure — a pattern common to dilutive offerings from pre-profitability technology companies.
The AI lab's IPO move is the most consequential market test of the current AI investment cycle — and the assumptions baked into that number deserve a close read.
Canada's largest railway says operations are continuing despite a strike by signalling technicians, but the labour action introduces scheduling risk and potential regulatory scrutiny that investors should watch.
Trial data for ivonescimab suggest the bispecific antibody may outperform a leading checkpoint inhibitor in certain non-small cell lung cancer patients — a result with meaningful commercial implications.
The horror film's debut weekend suggests renewed consumer appetite for theatrical releases — a data point with implications for studio valuations, streaming negotiations, and exhibition-sector credit.
Form 4 filings at two high-profile names — one a U.S. retail giant, the other a Chinese technology conglomerate — offer a narrow but useful signal about how insiders are positioning ahead of earnings season.
Tomas Chamorro-Premuzic contends that 'being yourself' at work is insufficient guidance for effective leadership—and may actively undermine professional performance.
A potential pill formulation of semaglutide is drawing investor attention back to Novo Nordisk, whose market capitalisation had lagged Lilly's by a widening margin. The balance-sheet and financing implications for both companies deserve scrutiny.
As regulated prediction markets gain traction in the U.S., a small set of publicly traded companies stands to benefit — though the investment case carries meaningful uncertainty.
A break-even analysis around age 78 frames the core trade-off, but survivor benefits, earnings limits, and longevity risk all shift the calculus.